Regeneron Pharmaceuticals (REGN) expands its focus on eye care with the acquisition of Oxular, a U.K.-based biotech ...

Frosted branch angiitis is a rare condition that makes the blood vessels that supply the retina look like the frosted ...

The patient, with a history of cardiovascular issues, presented with distorted central vision in the left eye for 3 weeks ... In the left eye, the thickest retinal area above the foveola contained a ...

Aortic Temporary occlusion of large blood vessels and/or circulatory support Invamed ICT Paravalvular Leak Closure Device Hard gel Deliverable by the delivery system Temporarily occlude and close ...

These elevated pressures can extend to ocular veins, resulting in complications such as central retinal vein occlusion (CRVO). This case report highlights a rare instance of CRVO combined with ...

Eylea HD results were consistent across patients with branch RVOs and those with central retinal or hemiretinal vein occlusions. In the past three months, shares of REGN have plunged 35.7% compare ...

Regeneron Pharmaceuticals REGN announced that it has met the primary endpoint in a late-stage study evaluating Eylea HD (aflibercept) Injection 8 mg to treat patients with macular edema following ...

It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc. GILD and GSK plc GSK had a few regulatory updates. Recap of the Week’s Most ...

In a recent study, the company and its partner Bayer compared Eylea HD to the original version of Eylea in patients with macular edema following retinal vein occlusion (RVO), a common cause of ...

D in patients with macular edema secondary to retinal vein occlusion (RVO), including those with central retinal vein occlusion, branch retinal vein occlusion, or hemiretinal vein occlusion.